Pfizer withdraws sickle cell disease treatment on risk of …
WEB2 days ago · Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks ...
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle ...
WEB1 day ago · Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the pandemic-era windfall. ... Reuters, the news and media ...
Pfizer Voluntarily Withdraws Sickle Cell Disease Treatment Oxbryta …
WEB1 day ago · In the second quarter of 2024, Oxbryta generated sales of $92 million, up 20% year-over-year. Pfizer added Oxbryta to its portfolio via its $5.4 billion buyout of Global Blood Therapeutics in 2022.
FDA is alerting patients and health care professionals about the ...
WEB1 day ago · Pfizer Inc., the manufacturer of Oxbryta, announced it is voluntarily withdrawing the medication from the market, ceasing distribution, and discontinuing all active clinical trials and expanded ...
Pfizer withdraws sickle cell disease treatment from all markets
WEB2 days ago · Budrul Chukrut | Lightrocket | Getty Images. U.S. drugmaker Pfizer said on Wednesday it is withdrawing its sickle cell disease therapy Oxbryta in all markets where it is approved and discontinuing ...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB3 days ago · Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer's decision is based on the totality of clinical data that now indicates the ...
Pfizer pulls sickle cell disease therapy Oxbryta from markets
WEB2 days ago · Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago. Pfizer will stop ...
Pfizer's Oxbryta Exit May Hasten Trials of Rival ... - U.S. News
WEB2 days ago · US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. ... Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in ...
EU regulator recommends suspension of Pfizer's sickle cell disease ...
WEB1 day ago · Sept 26 (Reuters) - The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's sickle cell disease drug Oxbryta on Thursday. EMA said new data raise ...
Pfizer to Withdraw Sickle Cell Drug Oxbryta Lots from World …
WEB2 days ago · Sep 25, 2024 2:51pm. By Sabela Ojea. Pfizer said it is voluntarily withdrawing all lots of its sickle cell drug Oxbryta in all markets where it is approved, two years after acquiring its parent ...